Safety Outcomes / Neurological/Mental Health

(A-326) A Collaborative Approach to Evaluate Risk Factors for a Rare Adverse Event Among Individuals with Multiple Sclerosis Exposed to Sphingosine 1-phosphate Receptor Modulators

(A-319) Assessing the Risk of Neurodevelopmental Disorders in Children Prenatally Exposed to β-Lactam Antibiotics

(A-323) Association Between 5alpha-Reductase Inhibitors and Risk of Developing Parkinson’s Disease in Patients with Benign Prostatic Hyperplasia: Evidence from a Prospective Cohort Study

(A-322) Associations between lisinopril and amlodipine use and risk of aneurysmal subarachnoid haemorrhage: A UK population-based cohort study

(A-324) DARWIN EU® - A multi-national network cohort study of the effect of doxycycline versus active comparators on the risk of suicidality in individuals with acne

(A-318) Early-life Antibiotic Exposure and the Risk of Neurodevelopmental Disorders: A Systematic Review and Meta-Analysis

(A-320) Evaluating the Impact of GLP-1RAs on Mental Health and Antidepressant Use: A Target Trial Emulation with Distributional NCO Calibration

(A-321) Risk of adverse opioid-related outcomes among adult Medicaid enrollees with new long-term prescription opioid use

(A-327) The risk of mortality in patients with Multiple Sclerosis treated with alemtuzumab compared to other disease modifying therapies: A cohort study with data from five countries

(A-325) Use of fluoroquinolones and the risk of seizures: a population-based cohort study